机构:[1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China[2]Gannan Medical University, Ganzhou, 341000, China[3]Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China[4]Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China医技科室病理科首都医科大学附属天坛医院[5]Melbourne School of Population and Global Health, The University of Melbourne, Victoria, 3010, Australia
Multiple myeloma is a hematological tumor with a malignant proliferation of myeloma cells. Although the survival time after treatment has improved, the recurrence rate of MM is still high. Choroideremia-like (CHML) protein is essential for the prenylation modification of various Rab proteins and it exerts biological effects on vesicle trafficking and signal transduction. However, little is identified about the relationship between CHML gene and MM. We integrated gene expression profiles of 1907 MM patients (1959 MM samples) from the 7 datasets. The relationship between CHML gene expression level and event-free survival (EFS), overall survival (OS), ISS stage, molecular subtype, relapse, therapy was analyzed. The differential gene exression profile of CHML-high MM group and CHML-low MM group and possible pathway related to CHML were conducted. Our data showed that EFS (P < 0.0001) and OS (P < 0.0001) in MM patients with high expression of CHML were lower than those with low CHML expression. The gene expression level of CHML was increased in subtypes of MM with poor prognosis, especially in proliferation subtype (P < 0.001). Cell division pathway (P < 0.01) was high enriched of the differential expressed genes of CHML-high group vs CHML-low group. CHML gene can be considered as an independent factor to evaluate the prognosis of MM. High expression of CHML is associated with poor survival, which is related to cell proliferation and cell division of myeloma cells.
基金:
This work was funded by interdisciplinary
medicine Seed Fund of Peking University
(BMU2018MB004), Beijing Natural Science
Foundation (7132183 and 7182178), National Natural
Science Foundation of China (81800195 and 81460315),
China Health Promotion Foundation
(CHPF-zlkysx-001), Scientific Research Foundation
(20141114) from Health Commission of Jiangxi
Province, and Science and Technology Research
Foundation (GJJ14676) from Educational Commission
of Jiangxi Province, China.
第一作者机构:[1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China[3]Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China[*1]Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, P.R. China.[*2]Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, No. 23 Qingnian Road, Zhanggong District, Ganzhou, 341000, P.R. China.
推荐引用方式(GB/T 7714):
Weilong Zhang,Ling Cao,Xiaoni Liu,et al.High expression of CHML predicts poor prognosis of multiple myeloma[J].JOURNAL OF CANCER.2019,10(24):6048-6056.doi:10.7150/jca.34465.
APA:
Weilong Zhang,Ling Cao,Xiaoni Liu,Xue He,Ye Zhang...&Hongmei Jing.(2019).High expression of CHML predicts poor prognosis of multiple myeloma.JOURNAL OF CANCER,10,(24)
MLA:
Weilong Zhang,et al."High expression of CHML predicts poor prognosis of multiple myeloma".JOURNAL OF CANCER 10..24(2019):6048-6056